Table 1.

Patients characteristics and treatments.

No.	Sex	Age at inclusion	Combination therapy					Pasireotide-LAR first evaluation				Pasireotide-LAR last evaluation
			Treatment	Duration (months)	RT	IGF-1 (ULN)	GH (ng/mL)	Dose (mg/28 d)	IGF-1 (ULN)	GH (ng/mL)	Status after evaluation	Dose (mg/28 d)	IGF-1 (ULN)	GH (ng/mL)	Status after evaluation
11	F	36.5	Lanreotide 120 mg/28 d Pegvisomant 40 mg/7 d	1.5	N	0.4	NA	60	0.7	1.9	OG	27	1.1	7.26	OG
2	F	65.3	Octreotide 30 mg/35 d Pegvisomant 140 mg/7 d	163.7	Y	0.6	NA	40	1.5	NA	STOP
3	F	38.1	Octreotide 30 mg/28 d Pegvisomant 60 mg/7 d	21.5	N	0.8	NA	60	0.9	6.1	STOP
4	M	40.3	Octreotide 30 mg/28 d Pegvisomant 60 mg/7 d	105.6	N	0.9	NA	40	0.5	2.5	OG	40	0.5	2.5	OG
5	H	47.5	Lanreotide 120 mg/28 d Pegvisomant 70 mg/7 d	31	N	0.9	NA	40	0.9	NA	OG	40	1.2	0.9	OG
6	F	43.3	Lanreotide 120 mg/28 d Pegvisomant 80 mg/7 d	47.2	N	0.9	NA	60	1.2	1.0	OG	60	1.1	2.0	OG
7	F	48.9	Octreotide 30 mg/21 d Cabergoline 3.5 mg/7 d	15.7	N	1.0	1.9	40	0.6	0.8	OG	40	0.5	0.5	OG
8	F	57.0	Lanreotide 120 mg/21 d Pegvisomant 100 mg/7 d	67.5	Y	1.0	NA	60	0.6	0.1	OG	60	0.6	0.2	OG
9	F	67.0	Lanreotide 120 mg/28 d Pegvisomant 105 mg/7 d	54.4	N	1.1	NA	40	1.0	0.8	OG	40	1.8	1.1	STOP
10	F	51.3	Lanreotide 120 mg/28 d Pegvisomant 200 mg/7 d	38.8	Y	1.1	NA	40	1.8	NA	OG	60	1.6	1.3	STOP
11	M	50.2	Octreotide 30 mg/28 d Cabergoline 3.5 mg/7 d	42.4	N	1.3	2.8	40	1.3	1.4	OG	60	0.9	NA	OG
12	M	26.5	Octreotide 30 mg/42 d Pegvisomant 100 mg/7 d	92.6	Y	1.7	NA	60	0.9	0.5	OG	60	0.9	0.2	OG
13	M	35.6	Octreotide 30 mg /28 d Cabergoline 3.5 mg/7 d	19.2	N	1.7	1.0	60	1.7	1.7	STOP
14	F	50.6	Lanreotide 120 mg/28 d Pegvisomant 120 mg/7 d	1.8	N	3.3	NA	40	1.3	1.8	OG	60	1.2	0.9	STOP
15	F	52.4	Octreotide 30 mg/28 d Cabergoline 3.5 mg/7 d	5.3	N	4.1	7.8	60	3.3	8.9	STOP

d, days; NA, non-available; OG, ongoing.